
Nicolas Chomont

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2273415/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Cellular Activation, Differentiation, and Proliferation Influence the Dynamics of Genetically Intact Proviruses Over Time. Journal of Infectious Diseases, 2022, 225, 1168-1178.	4.0	9
2	Camu Camu effects on microbial translocation and systemic immune activation in ART-treated people living with HIV: protocol of the single-arm non-randomised Camu Camu prebiotic pilot study (CIHR/CTN PT032). BMJ Open, 2022, 12, e053081.	1.9	3
3	The ingenol-based protein kinase C agonist GSK445A is a potent inducer of HIV and SIV RNA transcription. PLoS Pathogens, 2022, 18, e1010245.	4.7	11
4	Pembrolizumab induces HIV latency reversal in people living with HIV and cancer on antiretroviral therapy. Science Translational Medicine, 2022, 14, eabl3836.	12.4	50
5	The HIV-1 proviral landscape reveals that Nef contributes to HIV-1 persistence in effector memory CD4+ T cells. Journal of Clinical Investigation, 2022, 132, .	8.2	52
6	T cell migration potentiates HIV infection by enhancing viral fusion and integration. Cell Reports, 2022, 38, 110406.	6.4	6
7	Impact of Tamoxifen on Vorinostat-Induced Human Immunodeficiency Virus Expression in Women on Antiretroviral Therapy: AIDS Clinical Trials Group A5366, The MOXIE Trial. Clinical Infectious Diseases, 2022, 75, 1389-1396.	5.8	9
8	Persistent HIV transcription and variable antiretroviral drug penetration in lymph nodes during plasma viral suppression. Aids, 2022, 36, 985-990.	2.2	12
9	First-in-human immunoPET imaging of HIV-1 infection using 89Zr-labeled VRC01 broadly neutralizing antibody. Nature Communications, 2022, 13, 1219.	12.8	20
10	Combination Immune Checkpoint Blockade Enhances IL-2 and CD107a Production from HIV-Specific T Cells Ex Vivo in People Living with HIV on Antiretroviral Therapy. Journal of Immunology, 2022, 208, 54-62.	0.8	16
11	Willingness of Older Canadians with HIV to Participate in HIV Cure Research Near and After the End of Life: A Mixed-Method Study. AIDS Research and Human Retroviruses, 2022, 38, 670-682.	1.1	5
12	HIV persistence in subsets of CD4+ T cells: 50 shades of reservoirs. Seminars in Immunology, 2021, 51, 101438.	5.6	36
13	Continuous Prophylactic Antiretrovirals/Antiretroviral Therapy Since Birth Reduces Seeding and Persistence of the Viral Reservoir in Children Vertically Infected With Human Immunodeficiency Virus. Clinical Infectious Diseases, 2021, 73, 427-438.	5.8	13
14	Assessing the Suitability of Next-Generation Viral Outgrowth Assays to Measure Human Immunodeficiency Virus 1 Latent Reservoir Size. Journal of Infectious Diseases, 2021, 224, 1209-1218.	4.0	18
15	Intact Human Immunodeficiency Virus (HIV) Reservoir Estimated by the Intact Proviral DNA Assay Correlates With Levels of Total and Integrated DNA in the Blood During Suppressive Antiretroviral Therapy. Clinical Infectious Diseases, 2021, 72, 495-498.	5.8	23
16	Peculiar Phenotypic and Cytotoxic Features of Pulmonary Mucosal CD8 T Cells in People Living with HIV Receiving Long-Term Antiretroviral Therapy. Journal of Immunology, 2021, 206, 641-651.	0.8	5
17	Safety, Immune, and Antiviral Effects of Pegylated Interferon Alpha 2b Administration in Antiretroviral Therapy-Suppressed Individuals: Results of Pilot Clinical Trial. AIDS Research and Human Retroviruses, 2021, 37, 433-443.	1.1	9
18	Gag p24 Is a Marker of Human Immunodeficiency Virus Expression in Tissues and Correlates With Immune Response. Journal of Infectious Diseases, 2021, 224, 1593-1598.	4.0	14

#	Article	IF	CITATIONS
19	Differences in HIV burden in the inflamed and non-inflamed colon from a person living with HIV and ulcerative colitis. Journal of Virus Eradication, 2021, 7, 100033.	0.5	6
20	LILAC pilot study: Effects of metformin on mTOR activation and HIV reservoir persistence during antiretroviral therapy. EBioMedicine, 2021, 65, 103270.	6.1	46
21	Identification of SARS-CoV-2–specific immune alterations in acutely ill patients. Journal of Clinical Investigation, 2021, 131, .	8.2	24
22	Upregulated IL-32 Expression And Reduced Gut Short Chain Fatty Acid Caproic Acid in People Living With HIV With Subclinical Atherosclerosis. Frontiers in Immunology, 2021, 12, 664371.	4.8	25
23	Loss of CD96 Expression as a Marker of HIV-Specific CD8+ T-Cell Differentiation and Dysfunction. Frontiers in Immunology, 2021, 12, 673061.	4.8	5
24	RALDH Activity Induced by Bacterial/Fungal Pathogens in CD16+ Monocyte-Derived Dendritic Cells Boosts HIV Infection and Outgrowth in CD4+ T Cells. Journal of Immunology, 2021, 206, 2638-2651.	0.8	7
25	Long-term effects of early antiretroviral initiation on HIV reservoir markers: a longitudinal analysis of the MERLIN clinical study. Lancet Microbe, The, 2021, 2, e198-e209.	7.3	24
26	In-depth single-cell analysis of translation-competent HIV-1 reservoirs identifies cellular sources of plasma viremia. Nature Communications, 2021, 12, 3727.	12.8	43
27	Brief Report: Subclinical Carotid Artery Atherosclerosis Is Associated With Increased Expression of Peripheral Blood IL-32 Isoforms Among Women Living With HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 88, 186-191.	2.1	3
28	Increased homeostatic cytokines and stability of HIV-infected memory CD4 T-cells identify individuals with suboptimal CD4 T-cell recovery on-ART. PLoS Pathogens, 2021, 17, e1009825.	4.7	17
29	Combined single-cell transcriptional, translational, and genomic profiling reveals HIV-1 reservoir diversity. Cell Reports, 2021, 36, 109643.	6.4	34
30	IL-17A reprograms intestinal epithelial cells to facilitate HIV-1 replication and outgrowth in CD4+ TÂcells. IScience, 2021, 24, 103225.	4.1	3
31	Preferential and persistent impact of acute HIV-1 infection on CD4 ⁺ iNKT cells in colonic mucosa. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	2
32	Integrated immunovirological profiling validates plasma SARS-CoV-2 RNA as an early predictor of COVID-19 mortality. Science Advances, 2021, 7, eabj5629.	10.3	32
33	Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021. Nature Medicine, 2021, 27, 2085-2098.	30.7	146
34	Clinical Correlates of Human Immunodeficiency Virus–1 (HIV-1) DNA and Inducible HIV-1 RNA Reservoirs in Peripheral Blood in Children With Perinatally Acquired HIV-1 Infection With Sustained Virologic Suppression for at Least 5 Years. Clinical Infectious Diseases, 2020, 70, 859-866.	5.8	20
35	Viral Blips After Treatment Initiation During Acute Human Immunodeficiency Virus Infection. Clinical Infectious Diseases, 2020, 70, 2706-2709.	5.8	11
36	High levels of genetically intact HIV in HLA-DR+ memory T cells indicates their value for reservoir studies. Aids, 2020, 34, 659-668.	2.2	32

#	Article	IF	CITATIONS
37	Human Immunodeficiency Virus (HIV)–Infected CCR6+ Rectal CD4+ T Cells and HIV Persistence On Antiretroviral Therapy. Journal of Infectious Diseases, 2020, 221, 744-755.	4.0	39
38	A randomized trial of vorinostat with treatment interruption after initiating antiretroviral therapy during acute HIV-1 infection. Journal of Virus Eradication, 2020, 6, 100004.	0.5	23
39	Highlights of the 9th edition of the Conference on HIV Persistence During Therapy, 10–13 December 2019, Miami, USA. Journal of Virus Eradication, 2020, 6, 85-95.	0.5	0
40	Fingolimod inhibits multiple stages of the HIV-1 life cycle. PLoS Pathogens, 2020, 16, e1008679.	4.7	8
41	Single-cell TCR sequencing reveals phenotypically diverse clonally expanded cells harboring inducible HIV proviruses during ART. Nature Communications, 2020, 11, 4089.	12.8	77
42	Potential for Virus Endogenization in Humans through Testicular Germ Cell Infection: the Case of HIV. Journal of Virology, 2020, 94, .	3.4	15
43	HIV Infection and Persistence in Pulmonary Mucosal Double Negative T Cells In Vivo. Journal of Virology, 2020, 94, .	3.4	12
44	Recommendations for measuring HIV reservoir size in cure-directed clinical trials. Nature Medicine, 2020, 26, 1339-1350.	30.7	96
45	Genetic Diversity, Compartmentalization, and Age of HIV Proviruses Persisting in CD4 ⁺ T Cell Subsets during Long-Term Combination Antiretroviral Therapy. Journal of Virology, 2020, 94, .	3.4	21
46	â€~Rinse and Replace': Boosting T Cell Turnover To Reduce HIV-1 Reservoirs. Trends in Immunology, 2020, 41, 466-480.	6.8	26
47	Virologic and Immunologic Features of Simian Immunodeficiency Virus Control Post-ART Interruption in Rhesus Macaques. Journal of Virology, 2020, 94, .	3.4	13
48	Improving HIV Outgrowth by Optimizing Cell-Culture Conditions and Supplementing With all-trans Retinoic Acid. Frontiers in Microbiology, 2020, 11, 902.	3.5	15
49	Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption. Nature Medicine, 2020, 26, 498-501.	30.7	43
50	Abundant HIV-infected cells in blood and tissues are rapidly cleared upon ART initiation during acute HIV infection. Science Translational Medicine, 2020, 12, .	12.4	69
51	Combination Immune Checkpoint Blockade to Reverse HIV Latency. Journal of Immunology, 2020, 204, 1242-1254.	0.8	38
52	Preferential Infection of α4β7+ Memory CD4+ T Cells During Early Acute Human Immunodeficiency Virus Type 1 Infection. Clinical Infectious Diseases, 2020, 71, e735-e743.	5.8	14
53	The Biology of the HIV-1 Latent Reservoir and Implications for Cure Strategies. Cell Host and Microbe, 2020, 27, 519-530.	11.0	173
54	Persistent expansion and Th1-like skewing of HIV-specific circulating T follicular helper cells during antiretroviral therapy. EBioMedicine, 2020, 54, 102727.	6.1	42

#	Article	IF	CITATIONS
55	Impact of Antiretroviral Therapy Duration on HIV-1 Infection of T Cells within Anatomic Sites. Journal of Virology, 2020, 94, .	3.4	20
56	HIV enters deep sleep in people who naturally control the virus. Nature, 2020, 585, 190-191.	27.8	8
57	Neutralizing antibody VRC01 failed to select for HIV-1 mutations upon viral rebound. Journal of Clinical Investigation, 2020, 130, 3299-3304.	8.2	24
58	The multifaceted nature of HIV latency. Journal of Clinical Investigation, 2020, 130, 3381-3390.	8.2	49
59	Pharmacological Inhibition of PPAR _y Boosts HIV Reactivation and Th17 Effector Functions, while Preventing Progeny Virion Release and <i>de novo</i> Infection. Pathogens and Immunity, 2020, 5, 177.	3.1	12
60	Highlights of the 9th edition of the Conference on HIV Persistence During Therapy, 10-13 December 2019, Miami, USA. Journal of Virus Eradication, 2020, 6, 85-95.	0.5	0
61	Fingolimod inhibits multiple stages of the HIV-1 life cycle. , 2020, 16, e1008679.		0
62	Fingolimod inhibits multiple stages of the HIV-1 life cycle. , 2020, 16, e1008679.		0
63	Fingolimod inhibits multiple stages of the HIV-1 life cycle. , 2020, 16, e1008679.		0
64	Fingolimod inhibits multiple stages of the HIV-1 life cycle. , 2020, 16, e1008679.		0
65	Fingolimod inhibits multiple stages of the HIV-1 life cycle. , 2020, 16, e1008679.		0
66	Fingolimod inhibits multiple stages of the HIV-1 life cycle. , 2020, 16, e1008679.		0
67	Processing of Bronchoalveolar Lavage Fluid and Matched Blood for Alveolar Macrophage and CD4 ⁺ T-cell Immunophenotyping and HIV Reservoir Assessment. Journal of Visualized Experiments, 2019, , .	0.3	8
68	Memory CD4 + T-Cells Expressing HLA-DR Contribute to HIV Persistence During Prolonged Antiretroviral Therapy. Frontiers in Microbiology, 2019, 10, 2214.	3.5	38
69	Infrequent HIV Infection of Circulating Monocytes during Antiretroviral Therapy. Journal of Virology, 2019, 94, .	3.4	23
70	Oral cannabinoids in people living with HIV on effective antiretroviral therapy: CTN PT028—study protocol for a pilot randomised trial to assess safety, tolerability and effect on immune activation. BMJ Open, 2019, 9, e024793.	1.9	31
71	HIV Diversity and Genetic Compartmentalization in Blood and Testes during Suppressive Antiretroviral Therapy. Journal of Virology, 2019, 93, .	3.4	35
72	Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet HIV,the, 2019, 6, e297-e306.	4.7	73

#	Article	IF	CITATIONS
73	Effect of metformin on the size of the HIV reservoir in non-diabetic ART-treated individuals: single-arm non-randomised Lilac pilot study protocol. BMJ Open, 2019, 9, e028444.	1.9	39
74	Single-cell characterization and quantification of translation-competent viral reservoirs in treated and untreated HIV infection. PLoS Pathogens, 2019, 15, e1007619.	4.7	177
75	Modeling HIV-1 Latency Using Primary CD4 ⁺ T Cells from Virally Suppressed HIV-1-Infected Individuals on Antiretroviral Therapy. Journal of Virology, 2019, 93, .	3.4	9
76	PD-1 blockade potentiates HIV latency reversal ex vivo in CD4+ T cells from ART-suppressed individuals. Nature Communications, 2019, 10, 814.	12.8	149
77	Differentiation into an Effector Memory Phenotype Potentiates HIV-1 Latency Reversal in CD4 ⁺ T Cells. Journal of Virology, 2019, 93, .	3.4	72
78	Latency-Reversing Agents Induce Differential Responses in Distinct Memory CD4ÂT Cell Subsets in Individuals on Antiretroviral Therapy. Cell Reports, 2019, 29, 2783-2795.e5.	6.4	51
79	Upregulation of IL-32 Isoforms in Virologically Suppressed HIV-Infected Individuals: Potential Role in Persistent Inflammation and Transcription From Stable HIV-1 Reservoirs. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 82, 503-513.	2.1	21
80	Human Immunodeficiency Virus (HIV)-Antibody Repertoire Estimates Reservoir Size and Time of Antiretroviral Therapy Initiation in Virally Suppressed Perinatally HIV-Infected Children. Journal of the Pediatric Infectious Diseases Society, 2019, 8, 433-438.	1.3	29
81	Cellular Metabolism Is a Major Determinant of HIV-1 Reservoir Seeding in CD4+ T Cells and Offers an Opportunity to Tackle Infection. Cell Metabolism, 2019, 29, 611-626.e5.	16.2	124
82	Sex-Based Differences in Human Immunodeficiency Virus Type 1 Reservoir Activity and Residual Immune Activation. Journal of Infectious Diseases, 2019, 219, 1084-1094.	4.0	73
83	Acute Retroviral Syndrome Is Associated With High Viral Burden, CD4 Depletion, and Immune Activation in Systemic and Tissue Compartments. Clinical Infectious Diseases, 2018, 66, 1540-1549.	5.8	32
84	Wake me up before you go. Aids, 2018, 32, 293-298.	2.2	9
85	Highlights from the 8th International Workshop on HIV Persistence during Therapy, 12–15 December 2017, Miami, FL, USA. Journal of Virus Eradication, 2018, 4, 132-142.	0.5	0
86	A-108 The Contribution of memory CD4+ T cell subset phenotype to latency reversal efficiency. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 77, 35-35.	2.1	0
87	Anti-α4β7 therapy targets lymphoid aggregates in the gastrointestinal tract of HIV-1–infected individuals. Science Translational Medicine, 2018, 10, .	12.4	65
88	HIV persistence in mucosal CD4+ T cells within the lungs of adults receiving long-term suppressive antiretroviral therapy. Aids, 2018, 32, 2279-2289.	2.2	44
89	Estrogen receptor-1 is a key regulator of HIV-1 latency that imparts gender-specific restrictions on the latent reservoir. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E7795-E7804.	7.1	121
90	Inducible HIV RNA transcription assays to measure HIV persistence: pros and cons of a compromise. Retrovirology, 2018, 15, 9.	2.0	25

#	Article	IF	CITATIONS
91	Programmed cell death-1 contributes to the establishment and maintenance of HIV-1 latency. Aids, 2018, 32, 1491-1497.	2.2	136
92	Rapid HIV RNA rebound after antiretroviral treatment interruption in persons durably suppressed in Fiebig I acute HIV infection. Nature Medicine, 2018, 24, 923-926.	30.7	263
93	Distinct biomarker signatures in HIV acute infection associate with viral dynamics and reservoir size. JCI Insight, 2018, 3, .	5.0	32
94	Central Memory CD4 T Cells. , 2018, , 268-275.		0
95	Highlights from the 8 International Workshop on HIV Persistence during Therapy, 12-15 December 2017, Miami, FL, USA. Journal of Virus Eradication, 2018, 4, 132-142.	0.5	1
96	Delayed differentiation of potent effector CD8 ⁺ T cells reducing viremia and reservoir seeding in acute HIV infection. Science Translational Medicine, 2017, 9, .	12.4	95
97	Human Immunodeficiency Virus Persistence and T-Cell Activation in Blood, Rectal, and Lymph Node Tissue in Human Immunodeficiency Virus–Infected Individuals Receiving Suppressive Antiretroviral Therapy. Journal of Infectious Diseases, 2017, 215, 911-919.	4.0	95
98	Association of Arterial and Lymph Node Inflammation With Distinct Inflammatory Pathways in Human Immunodeficiency Virus Infection. JAMA Cardiology, 2017, 2, 163.	6.1	50
99	Identification of Genetically Intact HIV-1 Proviruses in Specific CD4 + T Cells from Effectively Treated Participants. Cell Reports, 2017, 21, 813-822.	6.4	304
100	Multiparametric characterization of rare HIV-infected cells using an RNA-flow FISH technique. Nature Protocols, 2017, 12, 2029-2049.	12.0	55
101	HIV persists in CCR6+CD4+ T cells from colon and blood during antiretroviral therapy. Aids, 2017, 31, 35-48.	2.2	122
102	Persistent, Albeit Reduced, Chronic Inflammation in Persons Starting Antiretroviral Therapy in Acute HIV Infection. Clinical Infectious Diseases, 2017, 64, 124-131.	5.8	200
103	The evaluation of risk-benefit ratio for gut tissue sampling in HIV cure research. Journal of Virus Eradication, 2017, 3, 212-217.	0.5	12
104	HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study. PLoS Medicine, 2017, 14, e1002417.	8.4	186
105	Extensive virologic and immunologic characterization in an HIV-infected individual following allogeneic stem cell transplant and analytic cessation of antiretroviral therapy: A case study. PLoS Medicine, 2017, 14, e1002461.	8.4	50
106	The evaluation of risk-benefit ratio for gut tissue sampling in HIV cure research. Journal of Virus Eradication, 2017, 3, 212-217.	0.5	11
107	Virological and immunological characteristics of HIV-infected individuals at the earliest stage of infection. Journal of Virus Eradication, 2016, 2, 43-48.	0.5	73
108	Initiation of antiretroviral therapy before detection of colonic infiltration by HIV reduces viral reservoirs, inflammation and immune activation. Journal of the International AIDS Society, 2016, 19, 21163.	3.0	37

#	Article	IF	CITATIONS
109	DNA/MVA Vaccination of HIV-1 Infected Participants with Viral Suppression on Antiretroviral Therapy, followed by Treatment Interruption: Elicitation of Immune Responses without Control of Re-Emergent Virus. PLoS ONE, 2016, 11, e0163164.	2.5	26
110	Loss of Function of Intestinal IL-17 and IL-22 Producing Cells Contributes to Inflammation and Viral Persistence in SIV-Infected Rhesus Macaques. PLoS Pathogens, 2016, 12, e1005412.	4.7	53
111	Residual inflammation and viral reservoirs. Current Opinion in HIV and AIDS, 2016, 11, 234-241.	3.8	107
112	International AIDS Society global scientific strategy: towards an HIV cure 2016. Nature Medicine, 2016, 22, 839-850.	30.7	395
113	Persistence of integrated HIV DNA in CXCR3 + CCR6 + memory CD4+ T cells in HIV-infected individua antiretroviral therapy. Aids, 2016, 30, 1511-1520.	Ils on 2.2	68
114	Antiretroviral drug transporters and metabolic enzymes in human testicular tissue: potential contribution to HIV-1 sanctuary site. Journal of Antimicrobial Chemotherapy, 2016, 71, 1954-1965.	3.0	46
115	HIV DNA Set Point is Rapidly Established in Acute HIV Infection and Dramatically Reduced by Early ART. EBioMedicine, 2016, 11, 68-72.	6.1	193
116	Single-Cell Characterization of Viral Translation-Competent Reservoirs in HIV-Infected Individuals. Cell Host and Microbe, 2016, 20, 368-380.	11.0	170
117	New insights into the heterogeneity of Th17 subsets contributing to HIV-1 persistence during antiretroviral therapy. Retrovirology, 2016, 13, 59.	2.0	90
118	Strategies for targeting residual HIV infection. Current Opinion in HIV and AIDS, 2016, 11, 359-361.	3.8	2
119	Immune tolerance properties of the testicular tissue as a viral sanctuary site in ART-treated HIV-infected adults. Aids, 2016, 30, 2777-2786.	2.2	45
120	Impaired gut junctional complexes feature late-treated individuals with suboptimal CD4+ T-cell recovery upon virologically suppressive combination antiretroviral therapy. Aids, 2016, 30, 991-1003.	2.2	55
121	Anti-HIV Antibody Responses and the HIV Reservoir Size during Antiretroviral Therapy. PLoS ONE, 2016, 11, e0160192.	2.5	26
122	CD4+ T Cells Expressing PD-1, TIGIT and LAG-3 Contribute to HIV Persistence during ART. PLoS Pathogens, 2016, 12, e1005761.	4.7	350
123	Virological and immunological characteristics of HIV-infected individuals at the earliest stage of infection. Journal of Virus Eradication, 2016, 2, 43-48.	0.5	45
124	A Novel Assay to Measure the Magnitude of the Inducible Viral Reservoir in HIV-infected Individuals. EBioMedicine, 2015, 2, 874-883.	6.1	242
125	Identification of novel HIV-1 dependency factors in primary CCR4+CCR6+Th17 cells via a genome-wide transcriptional approach. Retrovirology, 2015, 12, 102.	2.0	54
126	The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo. PLoS Pathogens, 2015, 11, e1005142.	4.7	445

#	Article	IF	CITATIONS
127	Markers of HIV reservoir size and immune activation after treatment in acute HIV infection with and without raltegravir and maraviroc intensification. Journal of Virus Eradication, 2015, 1, 116-122.	0.5	50
128	HIV persistence in the setting of antiretroviral therapy: when, where and how does HIV hide?. Journal of Virus Eradication, 2015, 1, 59-66.	0.5	71
129	Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. Science Translational Medicine, 2015, 7, 319ra206.	12.4	390
130	Nef promotes evasion of human immunodeficiency virus type 1-infected cells from the CTLA-4-mediated inhibition of T-cell activation. Journal of General Virology, 2015, 96, 1463-1477.	2.9	17
131	The Tat Inhibitor Didehydro-Cortistatin A Prevents HIV-1 Reactivation from Latency. MBio, 2015, 6, e00465.	4.1	188
132	HIV-1 Reservoir Dynamics after Vaccination and Antiretroviral Therapy Interruption Are Associated with Dendritic Cell Vaccine-Induced T Cell Responses. Journal of Virology, 2015, 89, 9189-9199.	3.4	33
133	How does the timing of antiretroviral therapy initiation in acute infection affect HIV reservoirs?. Current Opinion in HIV and AIDS, 2015, 10, 18-28.	3.8	99
134	Interleukin-21 combined with ART reduces inflammation and viral reservoir in SIV-infected macaques. Journal of Clinical Investigation, 2015, 125, 4497-4513.	8.2	104
135	HIV persistence in the setting of antiretroviral therapy: when, where and how does HIV hide?. Journal of Virus Eradication, 2015, 1, 59-66.	0.5	51
136	Markers of HIV reservoir size and immune activation after treatment in acute HIV infection with and without raltegravir and maraviroc intensification. Journal of Virus Eradication, 2015, 1, 116-122.	0.5	36
137	Activation of HIV Transcription with Short-Course Vorinostat in HIV-Infected Patients on Suppressive Antiretroviral Therapy. PLoS Pathogens, 2014, 10, e1004473.	4.7	437
138	Reduced markers of HIV persistence and restricted HIV-specific immune responses after early antiretroviral therapy in children. Aids, 2014, 28, 1015-1020.	2.2	108
139	Central Memory CD4 T Cells. , 2014, , 1-8.		0
140	HIV Antibody Characterization as a Method to Quantify Reservoir Size During Curative Interventions. Journal of Infectious Diseases, 2014, 209, 1613-1617.	4.0	48
141	Cross-Clade Ultrasensitive PCR-Based Assays To Measure HIV Persistence in Large-Cohort Studies. Journal of Virology, 2014, 88, 12385-12396.	3.4	198
142	CD4+ and CD8+ T Cell Activation Are Associated with HIV DNA in Resting CD4+ T Cells. PLoS ONE, 2014, 9, e110731.	2.5	88
143	A novel acute HIV infection staging system based on 4thgeneration immunoassay. Retrovirology, 2013, 10, 56.	2.0	93
144	The immunological synapse: the gateway to the <scp>HIV</scp> reservoir. Immunological Reviews, 2013, 254, 305-325.	6.0	38

#	Article	IF	CITATIONS
145	Immune activation and <scp>HIV</scp> persistence: implications for curative approaches to <scp>HIV</scp> infection. Immunological Reviews, 2013, 254, 326-342.	6.0	334
146	Programmed Death-1 Is a Marker for Abnormal Distribution of Naive/Memory T Cell Subsets in HIV-1 Infection. Journal of Immunology, 2013, 191, 2194-2204.	0.8	81
147	High Levels of CD2 Expression Identify HIV-1 Latently Infected Resting Memory CD4 ⁺ T Cells in Virally Suppressed Subjects. Journal of Virology, 2013, 87, 9148-9158.	3.4	91
148	A candidate anti-HIV reservoir compound, auranofin, exerts a selective â€~anti-memory' effect by exploiting the baseline oxidative status of lymphocytes. Cell Death and Disease, 2013, 4, e944-e944.	6.3	49
149	Interleukin-7 promotes HIV persistence during antiretroviral therapy. Blood, 2013, 121, 4321-4329.	1.4	199
150	Down-Regulation of CTLA-4 by HIV-1 Nef Protein. PLoS ONE, 2013, 8, e54295.	2.5	20
151	Design and Implementation of a Randomized Crossover Study of Valproic Acid and Antiretroviral Therapy to Reduce the HIV Reservoir. HIV Clinical Trials, 2012, 13, 301-307.	2.0	11
152	Profound metabolic, functional, and cytolytic differences characterize HIV-specific CD8 T cells in primary and chronic HIV infection. Blood, 2012, 120, 3466-3477.	1.4	70
153	An Analog of the Natural Steroidal Alkaloid Cortistatin A Potently Suppresses Tat-Dependent HIV Transcription. Cell Host and Microbe, 2012, 12, 97-108.	11.0	159
154	CD4 T cell nadir independently predicts the magnitude of the HIV reservoir after prolonged suppressive antiretroviral therapy. Journal of Clinical Virology, 2012, 53, 29-32.	3.1	89
155	Conference highlights of the 5th international workshop on HIV persistence during therapy, 6-9 December 2011, St. Maartin, West Indies. AIDS Research and Therapy, 2012, 9, 7.	1.7	2
156	The role of cytokines in the establishment, persistence and eradication of the HIV reservoir. Cytokine and Growth Factor Reviews, 2012, 23, 143-149.	7.2	54
157	The Colocalization Potential of HIV-Specific CD8+ and CD4+ T-Cells is Mediated by Integrin β7 but Not CCR6 and Regulated by Retinoic Acid. PLoS ONE, 2012, 7, e32964.	2.5	17
158	Towards an HIV cure: a global scientific strategy. Nature Reviews Immunology, 2012, 12, 607-614.	22.7	485
159	Valproic acid in association with highly active antiretroviral therapy for reducing systemic <scp>HIV</scp> â€I reservoirs: results from a multicentre randomized clinical study. HIV Medicine, 2012, 13, 291-296.	2.2	99
160	Potent suppression of HIV viral replication by a novel inhibitor of Tat. Retrovirology, 2012, 9, .	2.0	1
161	Impact of Multi-Targeted Antiretroviral Treatment on Gut T Cell Depletion and HIV Reservoir Seeding during Acute HIV Infection. PLoS ONE, 2012, 7, e33948.	2.5	276
162	Loss of memory B cells during chronic HIV infection is driven by Foxo3a- and TRAIL-mediated apoptosis. Journal of Clinical Investigation, 2012, 122, 2704-2704.	8.2	0

#	Article	IF	CITATIONS
163	Finding a cure for HIV: will it ever be achievable?. Journal of the International AIDS Society, 2011, 14, 4-4.	3.0	39
164	Gold drug auranofin restricts the viral reservoir in the monkey AIDS model and induces containment of viral load following ART suspension. Aids, 2011, 25, 1347-1356.	2.2	74
165	Maintenance of CD4+ T-cell memory and HIV persistence: keeping memory, keeping HIV. Current Opinion in HIV and AIDS, 2011, 6, 30-36.	3.8	74
166	Loss of memory B cells during chronic HIV infection is driven by Foxo3a- and TRAIL-mediated apoptosis. Journal of Clinical Investigation, 2011, 121, 3877-3888.	8.2	95
167	Peripheral Blood CCR4+CCR6+ and CXCR3+CCR6+ CD4+ T Cells Are Highly Permissive to HIV-1 Infection. Journal of Immunology, 2010, 184, 1604-1616.	0.8	279
168	HIV Persistence and the Prospect of Long-Term Drug-Free Remissions for HIV-Infected Individuals. Science, 2010, 329, 174-180.	12.6	274
169	HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nature Medicine, 2009, 15, 893-900.	30.7	1,519
170	P16-54 LB. Blood CCR6+ Th17 and Th1Th17 but not CCR6neg Th1 cells are targets for HIV replication and their frequency is diminished in HIV-infected subjects. Retrovirology, 2009, 6, P407.	2.0	0
171	Transcription factor FOXO3a controls the persistence of memory CD4+ T cells during HIV infection. Nature Medicine, 2008, 14, 266-274.	30.7	139
172	Neutralizing monoclonal antibodies to human immunodeficiency virus type 1 do not inhibit viral transcytosis through mucosal epithelial cells. Virology, 2008, 370, 246-254.	2.4	37
173	Lymph node architecture collapse and consequent modulation of FOXO3a pathway on memory T- and B-cells during HIV infection. Seminars in Immunology, 2008, 20, 196-203.	5.6	29
174	Opsonization of HIV with Complement Enhances Infection of Dendritic Cells and Viral Transfer to CD4 T Cells in a CR3 and DC-SIGN-Dependent Manner. Journal of Immunology, 2007, 178, 1086-1095.	0.8	57
175	Genetic and Phenotypic Features of Blood and Genital Viral Populations of Clinically Asymptomatic and Antiretroviral-Treatment-Naive Clade A Human Immunodeficiency Virus Type 1-Infected Women. Journal of Clinical Microbiology, 2007, 45, 1838-1842.	3.9	23
176	Drug resistance mutations and the cellular immune response: a valuable synergy for the development of novel immune therapies. Current Opinion in HIV and AIDS, 2007, 2, 116-122.	3.8	2
177	Programmed death 1: a critical regulator of T-cell function and a strong target for immunotherapies for chronic viral infections. Current Opinion in HIV and AIDS, 2007, 2, 219-227.	3.8	17
178	Early archives of genetically-restricted proviral DNA in the female genital tract after heterosexual transmission of HIV-1. Aids, 2007, 21, 153-162.	2.2	26
179	Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nature Medicine, 2006, 12, 1198-1202.	30.7	1,376
180	Enterovirus RNA shedding in the genital tract of childbearing-aged women living in Central Africa. Journal of Medical Virology, 2006, 78, 591-597.	5.0	2

#	Article	IF	CITATIONS
181	Independent Levels of Cellâ€Free and Cellâ€Associated Human Immunodeficiency Virus–1 in Genitalâ€Tract Secretions of Clinically Asymptomatic, Treatmentâ€Naive African Women. Journal of Infectious Diseases, 2003, 188, 549-554.	4.0	18
182	Comparison of Washing and Swabbing Procedures for Collecting Genital Fluids To Assess Shedding of Human Immunodeficiency Virus Type 1 (HIV-1) RNA in Asymptomatic HIV-1-Infected Women. Journal of Clinical Microbiology, 2003, 41, 449-452.	3.9	9
183	Opsonization of HIV-1 by Semen Complement Enhances Infection of Human Epithelial Cells. Journal of Immunology, 2002, 169, 3301-3306.	0.8	89
184	Binding of LFA-1 (CD11a) to Intercellular Adhesion Molecule 3 (ICAM-3; CD50) and ICAM-2 (CD102) Triggers Transmigration of Human Immunodeficiency Virus Type 1-Infected Monocytes through Mucosal Epithelial Cells. Journal of Virology, 2002, 76, 32-40.	3.4	30
185	Compartmentalization of HIV-1 between Breast Milk and Blood of HIV-Infected Mothers. Virology, 2002, 300, 109-117.	2.4	71
186	Active and Selective Transcytosis of Cell-Free Human Immunodeficiency Virus through a Tight Polarized Monolayer of Human Endometrial Cells. Journal of Virology, 2001, 75, 5370-5374.	3.4	75
187	Cervicovaginal Secretory Antibodies to Human Immunodeficiency Virus Type 1 (HIVâ€1) that Block Viral Transcytosis through Tight Epithelial Barriers in Highly Exposed HIVâ€1–Seronegative African Women. Journal of Infectious Diseases, 2001, 184, 1412-1422.	4.0	106
188	Opposite Effects of IL-10 on the Ability of Dendritic Cells and Macrophages to Replicate Primary CXCR4-Dependent HIV-1 Strains. Journal of Immunology, 2001, 166, 4244-4253.	0.8	44
189	Detection of Y Chromosome DNA as Evidence of Semen in Cervicovaginal Secretions of Sexually Active Women. Vaccine Journal, 2001, 8, 955-958.	2.6	35
190	Polymerase chain reaction for Y chromosome to detect semen in cervicovaginal fluid: a prerequisite to assess HIV-specific vaginal immunity and HIV genital shedding. Aids, 2001, 15, 801-802.	2.2	17